Organisation paid for research Program year 2025 Source: CMS Open Payments

121 Domenech Ave

Neither a doctor nor a teaching hospital

Research payments

$559,420

9 payments

Through program year 2025, 121 Domenech Ave is reported as receiving $559,420 in research payments, across 9 payments.

By program year

1 row

Year	Kind	Amount	Payments
2025	Research	$559,420	9

Breakdown

Who paid Research payments · program year 2025

Eli Lilly Export S.A. Puerto Rico Branch $505,943 3 payments
Eli Lilly and Company $53,477 6 payments

Studies the money was for Research payments · program year 2025

A Study of Remternetug Versus Placebo in Early Alzheimer's Disease Participants at Risk for Cognitive and Functional Decline $417,462 2 payments
Efficacy and Safety of Ixekizumab Or Ixekizumab Concomitantly Administered With Tirzepatide in Adult Participants With Active Psoriatic Arthritis and Obesity Or Overweight: A Phase 3B, Randomized, Multicenter, Open-Label Study (Together-Psa) $67,554 2 payments
A Phase 3B, Randomized, Multicenter, Controlled Study of Mirikizumab and Placebo Or Mirikizumab Concomitantly Administered With Tirzepatide in Adult Participants With Moderately to Severely Active Crohns Disease and Obesity Or Overweight $28,295 1 payment
A Phase 4, Multicenter, Open-Label, Single-Arm Study to Investigate the Efficacy of Lebrikizumab in Adult and Adolescent Participants With Atopic Dermatitis With Limited Body Surface Area Involvement and High Itch Burden (Adsolve) $23,668 1 payment
A Phase 3B, Randomized, Multicenter, Controlled Study of Mirikizumab and Placebo Or Mirikizumab Concomitantly Administered With Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity Or Overweight $21,740 1 payment
A Phase 3B, Randomized, Multicenter, Controlled Study of Mirikizumab and Placebo Or Mirikizumab Concomitantly Administered With Tirzepatide in Adult Participants With Moderately to Severely Active Crohns Disease and Obesity Or Overweight $426 1 payment
A Phase 3B, Randomized, Multicenter, Controlled Study of Mirikizumab and Placebo Or Mirikizumab Concomitantly Administered With Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity Or Overweight $274 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.